CMND — Clearmind Medicine Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapSucker Stock
- CA$3.80m
- -CA$0.85m
Annual income statement for Clearmind Medicine, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2018 October 31st | 2019 October 31st | 2020 October 31st | R2021 October 31st | 2022 October 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.195 | 0.105 | 0.233 | 3.69 | 8.53 |
| Operating Profit | -0.195 | -0.105 | -0.233 | -3.69 | -8.53 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.195 | -0.105 | -0.233 | -3.72 | -9.37 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.195 | -0.105 | -0.233 | -3.72 | -9.41 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.195 | -0.105 | -0.233 | -3.72 | -9.41 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.195 | -0.105 | -0.233 | -3.72 | -9.41 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.602 | -0.285 | -0.429 | -4 | -7.24 |